Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

By O. Michielin, A. V. Akkooi, P. Ascierto, R. Dummer, U. Keilholz. Annals of Oncology, 2019

719 citations recorded by the source corpus.

there was no difference in PFS between anti-PD1 antibody therapy versus a ipilimumab/nivolumab combination, in the PDL-1 positive population. The study was not powered to distinguish between the ef fi cacy of nivolumab and the ipilimumab/nivolumab combo. The fi nal clinical implications of this study, including the question about the superiority of combined anti-PD1/CTLA-4 therapy versus sequential anti-PD1/CTLA-4 therapy, remain open until the survival data are mature [41].

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c64fb02c9b65985fb26d94831c138a4cc2ff8d1a